Inogen downgraded to Underweight from Neutral at JPMorgan

JPMorgan downgraded Inogen to Underweight from Neutral with a price target of $8, down from $15. The company reported a disappointing update after the close on Monday as it paired the preannounced miss with significantly lower than expected 2023 guidance, the analyst tells investors in a research note. The firm thinks management has an “uphill battle ahead of it” before investors can get confident that the company’s growth challenges are transient and not market related.